Last Monday was one of my favorite holidays here in Canada. Victoria Day, which honors Queen Victoria’s birthday, kicks off the summer season, and we have an unwritten rule among the cousins in my family to gather at our family lake house after a long winter. Being able to…
Blade Therapeutics’ experimental oral therapy, Cudetaxestat (BLD-0409), was found to significantly reduce lung scarring (fibrosis) and the levels of fibrotic markers and pro-fibrotic molecules in a mouse model of pulmonary fibrosis. “Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model,” Blade said in…
Have you ever come across a painted rock? Are you familiar with the concept? People paint rocks and leave them in public areas for others to find. What they paint on the front of the rock is completely up to them. The underside typically offers information about the person…
It’s been one year since I joined Bionews, the publisher of Pulmonary Fibrosis News, as a columnist. At that point, I was trying to find my way in life with lymphocytic interstitial pneumonia (LIP) amid the COVID-19 pandemic. I never thought I’d have so much to write about.
Boehringer Ingelheim’s experimental oral therapy, BI 1015550, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), regardless of whether they were receiving approved anti-scarring therapies, according to final data from a Phase 2 clinical trial. “As the global market leader in pulmonary fibrosis, we have the ambition…
I was only 59 when I was diagnosed with idiopathic pulmonary fibrosis. I still had so many things to do, and many life experiences were waiting for me. I hadn’t yet walked my daughter, Heather, down the aisle. I didn’t have grandchildren. There were places my wife, Susan,…
The U.S. Food and Drug Administration (FDA) has given permission for Angion Biomedica to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with idiopathic pulmonary fibrosis (IPF). Angion is planning to launch the trial soon and expects that results will be…
Sandoz has launched a generic version of Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF) in the U.S. The new generic is available now via specialty pharmacies and there is a $0 co-pay program for eligible patients, according to Sandoz. “Sandoz is putting patients first…
As a millennial, I came of age with the internet. I remember the thrill of choosing the perfect screen name for AOL Instant Messenger before going to camp. (luv4pigs31, if you were wondering.) In eighth grade, I created my first social media account. Back in the early 2000s, Myspace was…
Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement in Ontario, Quebec, New Brunswick, Newfoundland and Labrador, Alberta, and the Northwest Territories. The therapy also will be reimbursed through the Non-Insured Health Benefits (NIHB) program, which provides eligible First…
Get regular updates to your inbox.
